Asahi Kasei agrees to acquire Bionova Scientific LLC
Asahi Kasei Medical concluded an agreement on April 14, 2022 (JST) through a U.S. subsidiary to wholly acquire Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies, especially those developing next-generation antibody based drugs.
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture. Its GMP manufacturing facility has state-of-the-art equipment including single-use bioreactors, suited to meet rising demand driven by the expansion of the antibody drug market and a steep increase in the number of biopharmaceuticals entering the clinical pipeline. Acquiring Bionova Scientific will enable Asahi Kasei Medical to add a biopharmaceutical CDMO (contract development and manufacturing organization) to its bioprocess business.
Related news and insights
Yumanity Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into a definitive agreement by which Kineta, Inc., will become a wholly-owned subsidiary of Yumanity in an all-stock transaction, resulting in a combined publicly traded company re-named Kineta, Inc., that will focus on immuno-oncology and continue Yumanity’s ongoing research collaboration with Merck & Co. in amyotrophic lateral sclerosis and frontotemporal lobar dementia.